BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
22.485
+0.075 (+0.33%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close22.410
Open22.350
Bid0.000 x 0
Ask0.000 x 0
Day's Range22.290 - 22.520
52 Week Range20.280 - 34.560
Volume1,075,183
Avg. Volume1,293,332
Market Cap83.377B
Beta (3Y Monthly)1.09
PE Ratio (TTM)10.09
EPS (TTM)2.228
Earnings DateN/A
Forward Dividend & Yield0.81 (3.63%)
Ex-Dividend Date2018-05-25
1y Target Est35.33
Trade prices are not sourced from all markets
  • Reuters3 days ago

    Brazil court denies Monsanto bid to halt seed licensing to bankrupt firm

    A Brazilian appeals court denied a request this month by Monsanto's local unit to suspend licensing of its popular Intacta soy seed technology to privately owned seed maker Sementes Talismã, according to a ruling seen by Reuters. Monsanto sought to suspend the licensing of the genetically modified seed technology after Talismã filed for bankruptcy protection in January, one of the seed maker's lawyers, Daniel Amaral of DASA Advogados in São Paulo, said. "Monsanto sought to end the licensing contract to try and negotiate better terms in Talismã's ongoing financial restructuring," Amaral said.

  • Reuters3 days ago

    Brazil court denies Monsanto bid to halt seed licensing to bankrupt firm

    A Brazilian appeals court denied a request this month by Monsanto's local unit to suspend licensing of its popular Intacta soy seed technology to privately owned seed maker Sementes Talismã, according to a ruling seen by Reuters. Monsanto sought to suspend the licensing of the genetically modified seed technology after Talismã filed for bankruptcy protection in January, one of the seed maker's lawyers, Daniel Amaral of DASA Advogados in São Paulo, said. "Monsanto sought to end the licensing contract to try and negotiate better terms in Talismã's ongoing financial restructuring," Amaral said.

  • Jurors: Don't throw out $289M weed killer cancer verdict
    Associated Press5 days ago

    Jurors: Don't throw out $289M weed killer cancer verdict

    SAN FRANCISCO (AP) — Jurors who found that agribusiness giant Monsanto's Roundup weed killer contributed to a school groundskeeper's cancer are urging a San Francisco judge not to throw out the bulk of their $289 million award in his favor, a newspaper reported Monday.

  • Barrons.com9 days ago

    Bayer Stock Is Battling Back Against Legal Worries

    The German health-care and chemical giant’s depressed shares have reflected the worst-case scenarios for its cancer-related challenges. Last week’s legal victory could be the first of several.

  • Champagne Remark May Cost Lawyer $289 Million Bayer Award
    Bloomberg9 days ago

    Champagne Remark May Cost Lawyer $289 Million Bayer Award

    Brent Wisner was the lead trial attorney who in August convinced a jury that Monsanto Co.’s Roundup weed killer caused his client’s cancer. The lawyer told jurors that Monsanto executives in a company board room were "waiting for the phone to ring" and that "behind them is a bunch of champagne on ice," according to a court filing.

  • The Wall Street Journal9 days ago

    [$$] Bayer Shares Jump in Germany After Roundup Ruling

    AG shares jumped Thursday in Germany after the company scored a provisional win in its rejection of a record jury award to a plaintiff who sought to hold the maker of Roundup weed killers liable for his non-Hodgkin lymphoma. Shares in the German chemicals and pharmaceuticals firm rose 3.1% in Germany, clawing back some of the sharp losses since a California jury in August ordered Monsanto, now owned by Bayer, to pay a total of $289 million in a landmark lawsuit over whether its weed killers cause cancer. Investors in Germany took relief after California Judge Suzanne Ramos Bolanos on Wednesday issued a tentative ruling for a new trial on the $250 million in punitive damages awarded to plaintiff Dewayne Johnson in the jury verdict that had spooked investors the company could face billions in potential plaintiff payouts.

  • Bayer Weighs Selling Its Vet Unit in Post-Monsanto Revamp
    Bloomberg10 days ago

    Bayer Weighs Selling Its Vet Unit in Post-Monsanto Revamp

    Bayer is evaluating animal health as part of a broader review, though a sale isn’t imminent, said the people, who asked not to be named because the appraisal hasn’t been made public. Bayer’s management is under pressure from large shareholders to sell assets, including the animal-health business, to help revive its share price, two people familiar with the matter said. Investors will be looking for an update on Bayer’s strategy when they meet the company for its Dec. 5 capital markets day in London.

  • Bayer lifted by likely new trial in $250 million weedkiller case
    Reuters10 days ago

    Bayer lifted by likely new trial in $250 million weedkiller case

    SAN FRANCISCO/FRANKFURT (Reuters) - The prospect of a fresh trial that could overturn $250 million damages against Bayer's (BAYGn.DE) Monsanto unit lifted the German company's shares, after an August ruling that it failed to warn users of the alleged cancer risks of its weedkillers. The original verdict wiped 10 percent off the value of the company and marked the first such decision against Monsanto and its glyphosate-containing weedkillers Roundup and Ranger Pro. Bayer, which bought Monsanto this year for $63 billion, faces more than 8,000 similar lawsuits in the United States.

  • Reuters10 days ago

    Bayer lifted by likely new trial in $250 million weedkiller case

    SAN FRANCISCO/FRANKFURT (Reuters) - The prospect of a fresh trial that could overturn $250 million damages against Bayer's (BAYGn.DE) Monsanto unit lifted the German company's shares, after an August ruling that it failed to warn users of the alleged cancer risks of its weedkillers. The original verdict wiped 10 percent off the value of the company and marked the first such decision against Monsanto and its glyphosate-containing weedkillers Roundup and Ranger Pro. Bayer, which bought Monsanto this year for $63 billion, faces more than 8,000 similar lawsuits in the United States.

  • Bayer Gains After Judge Favors Cutting Award in Roundup Case
    Bloomberg10 days ago

    Bayer Gains After Judge Favors Cutting Award in Roundup Case

    A San Francisco state judge indicated ahead of a hearing Wednesday on the company’s challenge to the August verdict that she’s inclined to set aside $250 million in punitive damages against Monsanto, which Bayer acquired this year. The judge said a comment by plaintiff’s attorney Brent Wisner, who told jurors that Monsanto executives were putting “Champagne on ice” in anticipation of a modest damage award, was one reason. Superior Court Judge Suzanne Ramos Bolanos said that even if she doesn’t vacate the punishment damages, she “would grant a new trial on grounds of insufficiency of the evidence to justify the award for punitive damages.” She also questioned whether the evidence introduced at trial supports the jury’s conclusion that Bayer was liable for plaintiff Lee Johnson’s non-Hodgkin lymphoma based on his exposure to the key ingredient in Roundup, called glyphosate.

  • The Wall Street Journal10 days ago

    [$$] Bayer Could Win a New Trial for Roundup

    Bayer AG could win a new trial to defend its Roundup weed killer. A California judge on Wednesday issued a tentative ruling for a new trial on the $250 million in punitive damages awarded to a groundskeeper, who sought to hold the Roundup maker liable for his non-Hodgkin lymphoma. If finalized, Judge Suzanne Ramos Bolanos’s ruling would grant a motion by Bayer arguing that sum wasn’t justified and that the evidence didn’t prove the company intended to harm the plaintiff.

  • California judge mulls new trial in $289M Roundup award
    Associated Press10 days ago

    California judge mulls new trial in $289M Roundup award

    SAN FRANCISCO (AP) — A San Francisco judge said Wednesday she is considering tossing out the lion's share of the $289 million judgment against agribusiness giant Monsanto and ordering a new trial over whether the company's weed-killer caused a groundskeeper's cancer.

  • The Latest: Judge weighs jury $289 million Monsanto verdict
    Associated Press10 days ago

    The Latest: Judge weighs jury $289 million Monsanto verdict

    SAN FRANCISCO (AP) — The Latest on $289 million verdict against Monsanto (all times local):

  • TheStreet.com10 days ago

    Bayer Wins Tentative Legal Victory in Roundup Cancer Case

    won a tentative court victory Wednesday after a San Francisco Superior Court Judge indicated she would vacate a $250 million jury verdict for punitive damages awarded to a groundskeeper who claimed his terminal cancer was caused by Roundup, a weed killer produced by Monsanto. San Francisco Superior Court Judge Suzanne Boloanos issued a tentative ruling saying she will likely order a new trial in the case, according to the San Francisco Chronicle. DeWayne Johnson, a former groundskeeper, claimed that the company failed to warn him and other users of the danger associated with Roundup exposure.

  • Bloomberg11 days ago

    Bayer Seeks to Wipe Out Roundup Verdict as New Trials Multiply

    If the company can persuade a judge to erase or chip away at the nine-figure verdict -- the first case to go to a jury among 8,700 people in the U.S. who blame the popular herbicide for their cancer -- legal experts say some plaintiffs may be less eager to pursue their claims. Bayer is also fighting to prevent a "rush to trial after trial" that it says will disrupt the orderly flow of litigation if a judge in California applies a rule that allows sick or old plaintiffs to jump to the head of the line. Jonas Oxgaard, an analyst at Sanford C. Bernstein & Co., estimates that Bayer’s market value is discounted by as much as $15 billion because the San Francisco verdict in August represents the larger cloud of Roundup liability trailing the company after it acquired Monsanto this year.

  • Simply Wall St.24 days ago

    Shareholders Should Check The Ownership Structure Of Bayer Aktiengesellschaft (FRA:BAYN)

    The big shareholder groups in Bayer Aktiengesellschaft (FRA:BAYN) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Read More...

  • Monsanto's Role in Roundup Safety Study Is Corrected by Journal
    Bloomberg24 days ago

    Monsanto's Role in Roundup Safety Study Is Corrected by Journal

    Bayer AG’s defense of Roundup weed killer may take a hit after an academic journal said Monsanto Co. didn’t fully disclose its involvement in published research finding the herbicide safe. A correction issued by Critical Reviews in Toxicology, a journal that analyzes health risks of chemicals, may bolster arguments that Monsanto, acquired by Bayer this year, ghost-wrote safety reviews as lawyers try to convince juries that Roundup causes cancer. Monsanto has defended the independence of the 2016 review, and the journal isn’t changing the papers’ scientific findings.

  • Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
    Zacks26 days ago

    Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx

    Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.

  • Reuterslast month

    Bayer hemophilia treatment wins thumbs-up from EU panel

    Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily. While final approvals are up to the European Commission, it generally follows recommendations from the Committee for Medicinal Products for Human Use (CHMP) and endorses them within a couple of months. The U.S. Food and Drug Administration last month approved https://in.reuters.com/article/us-bayer-fda/bayers-hemophilia-a-treatment-gets-u-s-fda-approval-idINKCN1LF17B the injection for previously treated patients and adolescents aged 12 years or older, judging it helped replace the reduced or missing protein, factor VIII, required to form blood clots.

  • Progenics Pharma's Stock Down on Dismal Phase III Study Data
    Zackslast month

    Progenics Pharma's Stock Down on Dismal Phase III Study Data

    Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.

  • The Wall Street Journallast month

    [$$] Bayer Steps Up Legal Fight Over Weed Killer Blamed for Cancer

    Bayer AG is stepping up the legal defense of its flagship weedkiller, after a recent verdict in a case alleging the chemical causes cancer sent shares down sharply and raised the prospect of costly plaintiff payouts. The German company on Tuesday said it wants a California state court judge to overturn the jury’s verdict, order a new trial or reduce damages, according to a court filing. The $289 million award granted in August came in one of the first of thousands of cases filed by gardeners, farmers and others claiming Bayer’s Roundup herbicide gave them cancer.

  • Monsanto asks judge to throw out $289M award in cancer suit
    Associated Presslast month

    Monsanto asks judge to throw out $289M award in cancer suit

    SAN FRANCISCO (AP) — Agribusiness company Monsanto has asked a San Francisco judge to throw out a jury's $289 million award to a former school groundskeeper who said the company's Roundup weed killer left him dying of cancer.

  • Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict
    Reuterslast month

    Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict

    The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson. Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate. Monsanto asked Superior Court Judge Suzanne Bolanos, who oversaw the trial, to set aside the verdict or, in the alternative, reduce the award or grant a new trial.

  • Reuterslast month

    Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict

    Bayer AG unit Monsanto on Tuesday asked a California judge to throw out a $289 million jury verdict awarded to a man who alleged the company's glyphosate-based weed-killers, including Roundup, gave him cancer. The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson. Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate.

  • Reuterslast month

    Bayer says agriculture trade flows may change amid tariffs dispute

    Bayer (BAYGn.DE) said on Tuesday it would be difficult to predict 2019 earnings at its agriculture business, which now includes Monsanto, because a U.S.-Chinese trade dispute could reroute global trade flows in farming commodities. The head of Bayer's crop science division told Reuters his company could even benefit if U.S. farmers switched to grow more corn to avoid barriers to the soy trade imposed by China in response to U.S. tariffs on Chinese products. "The big unknown next year will be how U.S. farmers react to the Chinese-U.S. trade war," Liam Condon said on the sidelines of a news conference at the division's headquarters in Monheim, Germany.